Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Cover
- DOCUMENT AND ENTITY INFORMATION
Financial Statements
Notes to Financial Statements
Accounting Policies
- Summary of Significant Accounting Policies (Policies)
Notes Tables
Notes Details

Sponsored Research and License Agreements (Details)

v3.19.3

Sponsored Research and License Agreements (Details) - USD ($)	1 Months Ended				3 Months Ended		9 Months Ended
	Oct. 31, 2019	Sep. 30, 2019	Jan. 31, 2019	Oct. 31, 2018	Sep. 30, 2019	Dec. 31, 2018	Sep. 30, 2019
Kissei
Collaborations
Upfront payment received				$ 33,000,000
Contingent payments				$ 147,000,000
Revenue recognized						$ 30,600,000
Grifols
Collaborations
Upfront payment received			$ 30,000,000				$ 5,000,000
Deferred revenue related to upfront payment		$ 25,400,000			$ 25,400,000		25,400,000
Grifols \| Research Services
Collaborations
Revenue recognized					71,000		215,000
Grifols \| Commercial Milestones
Collaborations
Contingent payments			297,500,000
Aclaris
Collaborations
Collaborative payment received		4,000,000
Revenue recognized					4,000,000		4,000,000
Celgene
Collaborations
Collaborative payment received		3,800,000
Revenue recognized					3,800,000		3,800,000
fostamatinib \| Kissei
Collaborations
Deferred revenue related to upfront payment		$ 1,400,000			1,400,000		1,400,000
Revenue recognized					$ 1,400,000		$ 1,600,000
fostamatinib \| Grifols \| Prior written notice following the second anniversary of the first MAA approval of fostamatinib in Europe and Turkey
Collaborations
Right to terminate agreement within number of months after second anniversary							6 months
fostamatinib \| Grifols \| Terminated agreement upon prior written notice within six months after second anniversary of agreement
Collaborations
Contingent upfront fee, refund requirement			25,000,000
fostamatinib \| Grifols \| Upon EMA approval of fostamatinib for treatment of chronic ITP
Collaborations
Contingent payments	$ 20,000,000		$ 20,000,000
fostamatinib \| Grifols \| Maximum
Collaborations
Royalty payment as a percentage of net sales			30.00%

- Definition

Represents the contingent amount of upfront fee refund requirement under certain terms of collaborative and licensing agreement.

+ References

No definition available.

+ Details

Name:	rigl_CollaborativeArrangementContingentUpfrontFeeRefundRequirement
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the amount of deferred revenue as of balance sheet date related to upfront payment under the collaborative and licensing agreement.

+ References

No definition available.

+ Details

Name:	rigl_CollaborativeArrangementDeferredRevenueRelatedToUpfrontPayment
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the revenue recognized during the period under the terms of sponsored research and license agreements.

+ References

No definition available.

+ Details

Name:	rigl_CollaborativeArrangementRevenueRecognized
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the right to terminate agreement within number of months after the second anniversary, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	rigl_CollaborativeArrangementRightToTerminateAgreementWithinNumberOfMonthsAfterSecondAnniversary
Namespace Prefix:	rigl_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the amount of upfront fees received during the period under the terms of collaborative and licensing agreement.

+ References

No definition available.

+ Details

Name:	rigl_CollaborativeArrangementUpfrontFeeReceived
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents additional contingent payments by entities.

+ References

No definition available.

+ Details

Name:	rigl_ContingentPaymentsUnderAgreement
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents royalty payment as a percentage of net sales.

+ References

No definition available.

+ Details

Name:	rigl_RoyaltyPaymentAsPercentageOfNetSales
Namespace Prefix:	rigl_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Cash received from collaborators during the current period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585

+ Details

Name:	us-gaap_ProceedsFromCollaborators
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	dei_LegalEntityAxis=rigl_KisseiPharmaceuticalCo.Ltd.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=rigl_GrifolsS.a.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rigl_AchievementOfMilestoneAxis=rigl_ResearchActivitiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rigl_AchievementOfMilestoneAxis=rigl_SpecifiedCommercialMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=rigl_AclarisTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=rigl_CelgeneCorporationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=rigl_FostamatinibMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementScenarioAxis=rigl_PriorWrittenNoticeFollowingSecondAnniversaryOfFirstMaaApprovalOfFostamatinibInEuropeAndTurkeyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementScenarioAxis=rigl_PriorWrittenNoticeWithinSixMonthsAfterSecondAnniversaryOfAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rigl_AchievementOfMilestoneAxis=rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: